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Atomic force microscopy (AFM) can be used to obtain the
physical information of single live cancer cells; however, the
physical changes in live cells with time based on AFM remain
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Evaluation of 5-ﬂuorouracil1 -treated lung cancer
cells by atomic force microscopy†
Xiaolin Jiang,a Ke Ma,*a Cuihua Hu, *a Mingyan Gao,a Jiashuo Zhang,b Ying Wang,a
Yujuan Chen, c Zhengxun Songa and Zuobin Wang*ad2
Atomic force microscopy4 (AFM) can be used to obtain the physical information of single live cancer cells;
however, the physical changes in live cells with time based on AFM remain to be studied, which play
a key role in the evaluation of the eﬃcacy and side eﬀects of drugs. Herein, the treatment of the A549
cell5 line with the anticarcinogen 5-ﬂuorouracil has been discussed based on the AFM analysis of their
continuous physical changes, including their surface morphology, height, adhesion and Young's
modulus, with time. In comparison, the African green monkey kidney (Vero) cell line was tested as
normal cells to determine the side eﬀects of 5-ﬂuorouracil. The results show that the optimal
concentration of 5-ﬂuorouracil is about 500 mM, which presents the best anticancer eﬀect and mild side
eﬀects.
1. Introduction
A World Health Organization (WHO) investigation in 2018
revealed that lung cancer ranks the third among serious human
diseases for both incidence and mortality with the rates of
22.5% and 18.4%, respectively.1 Lung cancer occupies a leading
status among cancer-related deaths, and non-small cell lung
cancer (NSCLC) shares are attributed to 80% of the total lung
cancer cases, of which the 5 year survival rate is only 20%.2–4
Most lung cancer patients are identied at an advanced stage,
and only radiation or chemotherapy treatment can work.
Chemotherapy treatment is the main method to treat lung
cancer, which is based on drugs and medicine.5,6 However,
these drugs always cause extreme side eﬀects to normal cells.
Therefore, it is important to evaluate their eﬃcacy and side
eﬀects with high accuracy.
5-Fluorouracil (5-FU) is a commonly6 used chemotherapeutic
drug for human cancers, and its eﬀectiveness for cancer treat-
ment has already been veried in clinic and experiment.7,8 Aer
penetrating the cancer cells, 5-FU is transformed into two major
active metabolites: FdUMP and FUTP. FdUMP interacts with
thymidylate synthase (TS) and 5,10-CH2-FH4 to form a covalent
ternary complex, thereby inhibiting the activity of TS and DNA
synthesis. Moreover, FUTP can interfere with RNA synthesis.9
Thus, by inhibiting the synthesis of DNA and RNA, 5-FU exhibits
a great value for cancer treatment. However, most of the drug
evaluationmethods are at the tissue and individual levels. Thus,
the nanomechanical property during single-cell apoptosis is
still unclear. Therefore, ultrahigh resolution microscopic
methods are needed for the detection of nanoscale physical
changes.
An atomic force microscope (AFM) has a sub-micrometric
resolution and is used in the biological eld to provide phys-
ical information of biological molecules10,11 and live cells.12–14
Thus, it provides a novel physical determination approach with
high accuracy. It can provide physical information, including
their surface morphology, height, adhesion and Young's
modulus, of single cells for quantitative analysis. The Young's
modulus is actually the result of complex tting and several
hypotheses of contact regime and tip properties, which lead to
signicant experimental uncertainty.15 However, the relative
modulus values show a close correlation with the true sample
properties. Thus, comprehensive and detailed data can be
obtained for single cell analysis.16–18 Moreover, the AFM images
can present the morphological changes of live cells aﬀected by
drugs, and the study on the cell membrane ultrastructure can
provide a better understanding of the growth and reproduction
of live cells.19–21 Hence, AFM is a suitable and accurate approach
to evaluate the eﬃcacy and side eﬀects of drugs in live cells.
Herein, the A549 cell line was used for the continuous
analysis of the physical changes with time before and aer
treatment with drugs based on AFM. 5-FU acts as an anticar-
cinogen,22,23which was used to treat the A549 cells with diﬀerent
concentrations. In addition, African green monkey kidney cells,
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known as Vero cells, were tested as normal cells to determine
the side eﬀects of 5-FU in under the same conditions. Accord-
ingly, the eﬃcacy and side eﬀects of the drug were determined
by analyzing the AFM data, such as surface morphology, height,
adhesion and Young's modulus.
2. Experimental
2.1 Cell culture
A549 (The Cell Bank of Type Culture Collection of Chinese
Academy of Sciences, Shanghai, China) and African green
monkey kidney cells, known as Vero cells (The Cell Bank of Type
Culture Collection of Chinese Academy of Sciences, Shanghai,
China), were cultured in a T25 cm2 culture ask using Roswell
Park Memorial Institute (RPMI)-1640 media (HyClone Co., USA)
with 10% fetal bovine serum (FBS, Gibco Co., USA) and 1%
antibiotics (penicillin–streptomycin solution, ThermoFisher
Co., USA). The culture asks were incubated in an incubator
(Sanyo, Japan) with 5% CO2 at 37 !C. The cells were subcultured
when they reached 85% conuence, and were washed twice
using PBS without calcium and magnesium followed by
detachment from the asks using 1 mL trypsin for 2 min at
37 !C in the cell culture incubator. Then 2 mL fresh culture
medium was added to terminate trypsin, and the mixture was
transferred to a centrifuge tube and centrifuged for 5 min at
1000 rpm. The supernatant was discarded, and the cells pellets
were diluted using freshmedia. The diluted cells were dispersed
on the a 38 mm culture dish and then cultured for 24 h before
use.
2.2 Preparation of 5-FU treatment solution
Commercial 5-FU powder (Aladdin Co., China) was dissolved in
RPMI-1640 media at a concentration of 5000 mM, which was
used as the 5-FU treatment solution and stored at 4 !C. It was
then diluted with RPMI-1640 media (10% FBS) to prepare the 5-
FU treatment solution with diﬀerent concentrations (0, 5, 10,
25, 50, 75, 100, 250, 500, 750 and 1000 mM), which was used for
the drug treatment on A549 and Vero cells.
2.3 Sample preparation
A549 and Vero cells were plated in diﬀerent culture dishes. Aer
24 h incubation, the cells were washed with phosphate buﬀered
saline (PBS) twice, and then diﬀerent concentrations (0, 500 and
1000 mM) of 5-FU treatment solution (2 mL) were added for
further incubation. Next, the cells were washed with PBS three
times to remove the dead cells, and 2 mL of RPMI-1640 medium
was added before AFM measurements.
2.4 Cell viability assay
A549 and Vero cells in the logarithmic growth phase were plated
(5.0 " 103 cells per well) in a 96-well plate (Kangning Co.) and
cultured in an incubator at 37 !C, 5% CO2 for 24 h. Aer
washing with PBS three times, the 5-FU treatment solution (200
mL) with diﬀerent concentrations (0, 5, 10, 25, 50, 75, 100, 250,
500, 750 and 1000 mM) was then added for another 48 h incu-
bation. Then 20 mL of MTT (Sigma-Aldrich, America) was added
to each well for another 4 h culture. The supernatant was
removed and 150 mL of DMSO was added to each well, and the
OD value at 492 nm was detected using a microplate spectro-
photometer (Epoch 2, BioTek, USA).
2.5 AFM analysis
A JPK system (NanoWizard®3, Germany) with an MLCT probe
(15 # 5 kHz resonance frequency, 0.03 # 0.02 N m$1 spring
constant, 20 nm tip curvature radius, 15! # 2.5! tip front angle,
25! # 2.5! tip back angle, and 17.5! # 2.5! tip side angle, Bruker,
Germany) was used for the measurement of the A549 and Vero
cells. The probe was used to scan the cells with 128" 128 pixels.
The 5-FU dosages of 0 mM, 500 mM and 1000 mM were used to
treat the cells with diﬀerent incubation time periods (0, 4, 8, 12,
24 and 48 h), and then the cells were measured by AFM (QI
mode with 1.2 nN setpoint) to analyze the surface morphology,
height, adhesion and Young's modulus of the cells.
3. Results and discussion
The MTT experimental data shown in Fig. 1 reects the eﬀect of
the dosage of 5-uorouracil (5-FU) on the A549 and Vero cells
aer 48 h cell culture. The cell viabilities of the both cell lines
decreased with an increase in the concentration of 5-FU from
0 mM to 1000 mM. Additionally, the results indicate that when
the concentration of 5-FU reached 500 mM, the A549 cells were
almost dead, and their survival rate wA below 2%, which is less
than that of the Vero cells (10%). Thus, the concentrations of
0 mM, 250 mM, 500 mM and 1000 mM were selected for the
following tests.
The AFM images shown in Fig. 2 7reect the continuous time
(from 0 h to 48 h) surface morphology changes in the A549 cells
and Vero cells treated with diﬀerent concentrations of 5-FU (0,
250, 500 and 1000 mM). Here, more than ten cells were
measured at a time to obtain the cell morphology. As shown in
Fig. 2 and S1,† the surface morphology of the A549 cells and
Fig. 1 Cell viabilities of A549 cells and Vero cells after 48 h treatment
with increasing concentrations of 5-ﬂuorouracil.
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Vero cells had no distinct change during the incubation time in
the absence of 5-FU, which reects that the cells grew in a good
condition within 48 h. Similarly, a low content of 5-FU (250 mM)
had little inuence on the cell growth in 48 h, illustrating that
the cells could not be killed by a low concentration of drug
(Fig. S2†). Aer treatment with 500 mM 5-FU, the A549 cells died
aer 24 h, but the Vero cells were still alive in an unhealthy
status aer the same period. This indicates that 500 mM 5-FU
has ascertainable anticancer eﬃcacy on the A549 cells and mild
side eﬀect on the Vero cells within 24 h. As the concentration of
5-FU increased to 1000 mM, the time for apoptosis to occur in
the Vero cells shied to an earlier time of 24 h and 12 h for the
A549 cells. This demonstrates that the drug concentration has
a serious side eﬀect on the Vero cells in 24 h. Therefore, 500 mM
of 5-FU should be the preferred concentration with good anti-
cancer eﬃcacy for NSCLC cells and mild side eﬀects for normal
cells.
Besides, the loss of cell volume signals cell death.24,25 As
shown in Fig. S3† corresponding to Fig. 2, cell deformation and
membrane collapse appeared in the presence of 5-FU. Also, the
cell volume loss deteriorated with an extension in the treatment
time. Thus, cell volume loss is a direct character to evaluate
drug eﬃciency.
The cell height variation with time quantitatively corre-
sponds to the cell condition in accordance with the
morphology. Aer drug treatment with 0 mM or 250 mM 5-FU,
the A549 cell height decreased at 8–10 h and then recovered
(Fig. 3), indicating that A549 cells undergo mitosis in 8 h and
then continue growing. For the Vero cells, the cell height
declined at 0–2 h and 6–8 h, indicating that the Vero cells
experienced two mitosis processes. While, aer treatment with
500 mM 5-FU, both the A549 and Vero cells went through one
mitosis process at 6–8 h and then continued growing. Moreover,
under the treatment of 1000 mM 5-FU, the A549 cell height
declined at 10 h, indicating that the A549 cells directly entered
the apoptotic phase without undergoing any mitosis process.
Whereas, the Vero cells underwent a mitosis process at 2–4 h
and then kept growing aerward. In general, the addition of
diﬀerent 5-FU concentrations had an eﬀect on the cell height,
where a higher concentration of drug resulted in a lower cell
height.
The adhesion map of A549 cells and Vero cells was investi-
gated (Fig. S4†), which represents the adhesion force between
the unfunctionalized AFM tip and cell. Without the drug treat-
ment, the adhesion force of the A549 cells showed no change
until a sudden reduction appeared at 8 h, indicating that the
mitosis process can reduce the cell adhesion force (Fig. 4). The
cell adhesion force remained stable aer 8 h, indicating that the
cell growth has no eﬀect on the adhesion force of A549 cells. In
comparison, the adhesion force of the Vero cells remained
stable during 48 h, which demonstrates that the cell mitosis and
cell growth had no eﬀect on the adhesion ability of the Vero
cells. Aer treatment with 250 mM 5-FU, the adhesion force of
both A549 cells and Vero cells exhibited no change compared to
that without drug treatment. Similarly, the adhesion force of
both A549 cells and Vero cells treated with 500 mM exhibited
a consistent trend, illustrating that the concentration of 500 mM
has a slight inuence on the cell adhesion force. However, in
Fig. 2 Morphology of A549 cells and Vero cells treated with diﬀerent concentrations of 5-ﬂuorouracil (0 and 500 mM) after diﬀerent incubation
times (0, 12, 24 and 48 h); scale bars: 20 mm.
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the presence of 1000 mM 5-FU, the adhesion force of the A549
cells increased gradually and then decreased rapidly. This
indicates that the high concentration of drug increased the cell
adhesion force, and then the dead cells led to a decline in cell
adhesion. In comparison, the adhesion force of the Vero cells
showed a wavy decrease due to the excessive drug intake and
excretion during the mitosis process. Aer the mitosis process,
the adhesion force remained unchanged. Therefore, the exces-
sive drug concentration will vastly increase the adhesion force
of both A549 and Vero cells within a certain period (2–8 h). As
shown in Fig. S5,† the changing tendency of the cell retraction
force is similar to that of the cell adhesion force.26 However, the
cell retraction force was lower than cell adhesion force due to
van der Waals force and repulsive force.27
The Young's modulus explains the elasticity of the cell
membrane. The Young's modulus map of the A549 cells and
Vero cells is shown in Fig. S6,† and the relative Young's
modulus parameters are presented in Fig. 5. The Young's
modulus of both A549 cells and Vero cells remained relatively
stable in the absence of drug, illustrating that the mitosis
process generally does not aﬀect the cell membrane elasticity.
Additionally, under the treatment of 250 mM 5-FU, the Young's
modulus tendency underwent a slight change. Thus, the low-
dose treatment did not aﬀect the Young's modulus of the
cells. However, aer treatment with 500 mM 5-FU, the Young's
modulus of the A549 cells showed a wave-like pattern, changing
every two hours due to the drug intake and excretion during the
mitosis process. Finally, the Young's modulus reached
a minimum value at 24 h due to cell death. On the contrary, the
Young's modulus of the drug-treated Vero cells exhibited
a moderate decline compared to the cells without the drug
treatment. This indicates that the cell surface elasticity of the
normal cell membrane can be reduced by drug intake. When
the drug concentration increased to 1000 mM, the Young's
modulus of the A549 cells exhibited a sharp increase and
Fig. 3 Cell height of A549 cells (a) and Vero cells (b) after treatment with diﬀerent concentrations of 5-ﬂuorouracil (0, 250, 500 and 1000 mM)
within a constant incubation time (0, 2, 4, 6, 8, 10, 12, 24, and 48 h) (data presented as the mean # SE. *P < 0.05; **P < 0.01; and ***P < 0.001
compared with the 0 mM group).
Fig. 4 Adhesion force of A549 cells (a) and Vero cells (b) after treat-
ment with diﬀerent concentrations of 5-ﬂuorouracil (0, 250, 500 and
1000 mM) within a continuous incubation time (0, 2, 4, 6, 8, 10, 12, 24
and 48 h) (data presented as the mean# SE. *P < 0.05; **P < 0.01; and
***P < 0.001 compared with the 0 mM group).
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showed a similar wavy changing tendency compared with the
cells treated with 500 mM 5-FU. However, the Young's modulus
of the A549 cells presented a rather high value probably due to
the excessive drug intake. Aer the high concentration of drug
intake, the Young's modulus of the cancer cells underwent
a rapid increase and then a slight decline. This decline trend
was not obvious because a high dose of drug remained inside
the dead cells, resulting in the high Young's modulus value
compared to the cells treated with a suitable dose of drug.
Meanwhile, the Young's modulus of the Vero cells presented
a stable variation trend under low-dose treatment (0 mMand 250
mM 5-FU) and the high-dose treatment initially increased their
Young's modulus. Contrary to the A549 cells, the Young's
modulus of the Vero cells was much lower aer the high-dose
treatment. This is probably because the Vero cells could not
intake the high dose of drug, and a large amount of drug
remained in the culture medium. Subsequently, the decline in
Young's modulus is probably due to cell mitosis, which eﬃ-
ciently decreased the drug concentration in the cells. Aer the
mitosis process, the cells kept swallowing the drug and the
Young's modulus increased again. Finally, the Young's modulus
was constantly reduced when the cells enter the apoptosis
phase. It should be noted that the Young's modulus was
calculated using Hertz/Sneddon model tting. Additionally,
uncertainties are inevitably caused by the probe, such as tip
shape, tip size, contact point and Poisson ratio.15 Therefore, the
relative diﬀerence between samples is more meaningful for
studying the mechanical properties of cells before and aer
drug treatment.
Actually, cell physical changes signicantly contribute to
cellular growth.28,29 This study clearly showed the continuous
changes in cell surface morphology, height, adhesion force and
Young's modulus with time at diﬀerent concentrations of 5-
uorouracil. Simultaneously, the drug eﬃcacy and side eﬀects
of 5-uorouracil in live cells were analyzed. The calculated
physical change in adhesion (Fig. 4 and S2†) and Young's
modulus (Fig. 5 and S3†) can be used as an eﬀective value to
evaluate the eﬀects of 5-FU and other biological molecules on
cancer cells. Therefore, the results provide new evidence for
pharmacodynamic assay.
4. Conclusion
In conclusion, the optimal concentration of 5-FU was 500 mM. At
this concentration, the time for apoptosis to occur in A549 cells
and Vero cells was 24 h and 48 h, respectively. During this
period, the height, adhesion and Young's modulus of the A549
cells and Vero cells varied moderately. This suggests that 500
mM 5-FU was capable of killing A549 cells with mild side eﬀects
on the Vero cells in 24 h. However, excessive drug (1000 mM)
resulted in the apoptosis of the A549 cells in 12 h and Vero cells
in 24 h, which interrupted the metabolism process of the Vero
cells with a serious side eﬀect. Therefore, the concentration of
500 mM of 5-FU presented the best anticancer eﬀect with mild
side eﬀects.
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